Zalicus Sees Significant Decrease in Short Interest (ZLCS)
Shares of Zalicus (NASDAQ:ZLCS) saw a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 759,728 shares, a decline of 32.0% from the April 15th total of 1,117,887 shares, Analyst Ratings News reports. Currently, 2.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,009,599 shares, the days-to-cover ratio is presently 0.4 days.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of Zalicus in a research note on Friday, May 9th. They now have a $1.00 price target on the stock.
Shares of Zalicus (NASDAQ:ZLCS) opened at 1.04 on Tuesday. Zalicus has a 52 week low of $0.86 and a 52 week high of $8.28. The stock has a 50-day moving average of $1.11 and a 200-day moving average of $1.41. The company’s market cap is $27.2 million.
Zalicus (NASDAQ:ZLCS) last released its earnings data on Friday, May 9th. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.20 by $0.35. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $9.00 million. Analysts expect that Zalicus will post $-0.16 EPS for the current fiscal year.
Zalicus Inc, formerly CombinatoRx, Incorporated, is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain and inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.